// App-Quantinova.ai

440 : Circulating tumor cells as predictive marker in panitumumab after progression of cetuximab in Japanese patients with KRAS wild-type metastatic colorectal cancer.

Researchers

Presenter

  • Yoshihito Ohhara

Principal Investigators

  • Satoshi Matsusaka

  • Eiji Shinozaki

  • Mitsukuni Suenaga

  • Nobuyuki Mizunuma

  • Kiyohiko Hatake

  • Toshiharu Yamaguchi

Medical Centers

  • Division of Gastroenterological Surgery, Gastroenterology Center, Cancer Institute Hospital, Tokyo, Japan

  • Department of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan

  • Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation For Cancer Research, Tokyo, Japan

  • Department of Radiology, Okayama University Graduate School of Medicine, Okayama, Japan

  • Department of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan

  • Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • Circulating tumor cells

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • panitumumab

  • Erbitux

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved